Tosymra (sumatriptan; Upsher Smith Laboratories) nasal spray is now available for the acute treatment of migraine with or without aura in adults.
Tosymra is an intranasal spray containing sumatriptan 10mg, a selective 5-HT1B/1D receptor agonist. The spray contains a permeation-enhancing excipient (Intravail), which allows the product to be quickly absorbed into the systemic circulation while demonstrating a similar pharmacokinetic profile as subcutaneous (SC) sumatriptan. In addition, results from a pharmacokinetic study comparing Tosymra 10mg to another intranasal sumatriptan (20mg) in healthy individuals showed that Tosymra had a more rapid absorption profile.
The product is supplied as a ready-to-use, single-dose, disposable unit; each carton contains 6 units. In an open-label trial, 46% of patients treated with Tosymra had local irritative symptoms including application site reaction, dysgeusia, and throat irritation.
“Tosymra Nasal Spray offers an alternative for patients whose symptoms interfere with taking oral medication or who may be dissatisfied with their current treatment regimen,” said Rusty Field, CEO of Upsher-Smith.
Upsher-Smith acquired Tosymra from Dr. Reddy’s Laboratories in June 2019.
For more information visit uphsher-smith.com.
This article originally appeared on MPR